Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Galan, M.C.; Venot, A.P.; Boons, G.J.
    Glycosyltransferase activity can be modulated by small conformational changes of acceptor substrates (2003), Biochemistry, 42, 8522-8529.
    View publication on PubMed

Cloned(Commentary)

EC Number Cloned (Comment) Organism
2.4.1.65 stable expression of FucT IV and IV in CHO cells Homo sapiens

KM Value [mM]

EC Number KM Value [mM] KM Value Maximum [mM] Substrate Comment Organism Structure
2.4.1.65 0.075
-
 Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester pH 6.5, 37°C, recombinant FucT VI Homo sapiens
2.4.1.65 0.12
-
 (Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me pH 6.5, 37°C, recombinant FucT VI Homo sapiens
2.4.1.65 0.35
-
 Galbeta(1-3)GlcNAcbeta-O-Me pH 6.5, 37°C, recombinant FucT VI Homo sapiens
2.4.1.65 0.4
-
 N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide pH 6.5, 37°C, recombinant FucT VI Homo sapiens
2.4.1.65 0.61
-
 N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide pH 6.5, 37°C, recombinant FucT VI Homo sapiens
2.4.1.65 1.1
-
 N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide pH 6.5, 37°C, recombinant FucT VI Homo sapiens
2.4.1.65 1.2
-
 Galbeta(1-3)GlcNAcbeta-O-Me pH 6.5, 37°C, recombinant FucT IV Homo sapiens
2.4.1.65 1.3
-
 Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester pH 6.5, 37°C, recombinant FucT IV Homo sapiens
2.4.1.65 2.7
-
 (Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me pH 6.5, 37°C, recombinant FucT IV Homo sapiens
2.4.1.65 3
-
 N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide pH 6.5, 37°C, recombinant FucT VI Homo sapiens
2.4.1.65 5
-
 N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide pH 6.5, 37°C, recombinant FucT IV Homo sapiens
2.4.1.65 11
-
 N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide pH 6.5, 37°C, recombinant FucT IV Homo sapiens
2.4.1.65 16
-
 N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide pH 6.5, 37°C, recombinant FucT IV Homo sapiens
2.4.1.65 25
-
 N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide pH 6.5, 37°C, recombinant FucT IV Homo sapiens
2.4.3.1 1
-
 N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide pH 6.5, 37°C Rattus norvegicus
2.4.3.1 1.1
-
 N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide pH 6.5, 37°C Rattus norvegicus
2.4.3.1 1.7
-
 Galbeta(1-3)GlcNAcbeta-O-Me pH 6.5, 37°C Rattus norvegicus
2.4.3.1 3.3
-
 Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester pH 6.5, 37°C Rattus norvegicus
2.4.3.1 11.2
-
 (Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me pH 6.5, 37°C Rattus norvegicus
2.4.3.1 11.6
-
 N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide pH 6.5, 37°C Rattus norvegicus

Metals/Ions

EC Number Metals/Ions Comment Organism Structure
2.4.1.65 Mn2+
-
 Homo sapiens

Organism

EC Number Organism UniProt Comment Textmining
2.4.1.65 Homo sapiens
-
-
-
2.4.3.1 Rattus norvegicus
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
2.4.3.1 liver
-
 Rattus norvegicus
-

Specific Activity [micromol/min/mg]

EC Number Specific Activity Minimum [µmol/min/mg] Specific Activity Maximum [µmol/min/mg] Comment Organism
2.4.1.65 additional information
-
 substrate specificity of FucT IV and FucT VI Homo sapiens

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.4.1.65 GDP-L-fucose + (Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
 Homo sapiens GDP + Fucalpha(1-3)(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
 ?
2.4.1.65 GDP-L-fucose + formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
-
 Homo sapiens GDP + ?
-
 ?
2.4.1.65 GDP-L-fucose + Galbeta(1-3)GlcNAcbeta-O-Me
-
 Homo sapiens GDP + Fucalpha(1-3)Galbeta(1-3)GlcNAcbeta-O-Me
-
 ?
2.4.1.65 GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide low activity with FucT IV and FucT VI Homo sapiens GDP + N-[(1R,3R,5R,6S,7S,8R,13R,15R,16R,17S)-6,17-dihydroxy-5-hydroxymethyl-15-methoxy-7-((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl]-acetamide
-
 ?
2.4.1.65 GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
-
 Homo sapiens GDP + N-[(1R,3R,5R,6S,7S,8R,13R,15R,16R,17S)-6,17-dihydroxy-5-hydroxymethyl-15-methoxy-7-((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl]-acetamide
-
 ?
2.4.1.65 GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
 Homo sapiens GDP + ?
-
 ?
2.4.1.65 GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
 Homo sapiens GDP + ?
-
 ?
2.4.1.65 GDP-L-fucose + N-acetyllactosamine
-
 Homo sapiens GDP + alpha-1,3-L-fucosyl-N-acetyllactosamine
-
 ?
2.4.1.65 additional information substrate specificity of FucT IV and FucT VI with N-acetyllactosamine derivatives, determination of the required conformational properties of oligosaccharide acceptors Homo sapiens ?
-
 ?
2.4.3.1 CMP-N-acetylneuraminate + (Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me 50% of the activity with Galbeta(1-3)GlcNAcbeta-O-Me Rattus norvegicus CMP + ?
-
 ?
2.4.3.1 CMP-N-acetylneuraminate + formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester as active as Galbeta(1-3)GlcNAcbeta-O-Me Rattus norvegicus CMP + ?
-
 ?
2.4.3.1 CMP-N-acetylneuraminate + Galbeta(1-3)GlcNAcbeta-O-Me
-
 Rattus norvegicus CMP + NeuAcalpha(2-6)Galbeta(1-3)GlcNAcbeta-O-Me
-
 ?
2.4.3.1 CMP-N-acetylneuraminate + N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide as active as Galbeta(1-3)GlcNAcbeta-O-Me Rattus norvegicus CMP + ?
-
 ?
2.4.3.1 CMP-N-acetylneuraminate + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide 110% of the activity with Galbeta(1-3)GlcNAcbeta-O-Me Rattus norvegicus CMP + ?
-
 ?
2.4.3.1 CMP-N-acetylneuraminate + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide 130% of the activity with Galbeta(1-3)GlcNAcbeta-O-Me Rattus norvegicus CMP + ?
-
 ?

Synonyms

EC Number Synonyms Comment Organism
2.4.1.65 fucosyltransferase IV
-
 Homo sapiens
2.4.1.65 fucosyltransferase VI
-
 Homo sapiens
2.4.1.65 FucT IV
-
 Homo sapiens
2.4.1.65 FucT VI
-
 Homo sapiens
2.4.3.1 R-2,6-sialyltransferase
-
 Rattus norvegicus

Temperature Optimum [°C]

EC Number Temperature Optimum [°C] Temperature Optimum Maximum [°C] Comment Organism
2.4.1.65 37
-
 assay at Homo sapiens

pH Optimum

EC Number pH Optimum Minimum pH Optimum Maximum Comment Organism
2.4.1.65 6.5
-
 assay at Homo sapiens